Cue Biopharma (CUE) Assets Average (2018 - 2025)

Cue Biopharma has disclosed Assets Average across 8 years of filings, most recently posting $36.9 million for Q4 2025.

• Assets Average for Q4 2025 came in at $36.9 million, down 4.08% year-over-year; the trailing twelve-month figure through Dec 2025 was $36.9 million (down 4.08% YoY), and the FY2025 annual result was $37.2 million, down 20.61% from the prior year.
• Assets Average came in at $36.9 million for Q4 2025 at Cue Biopharma, up from $36.2 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $94.1 million in Q1 2021 to a low of $27.2 million in Q1 2025.
• The 5-year median for Assets Average is $74.2 million (2023), against an average of $65.4 million.
• Across the five-year window, Assets Average soared 42.34% in 2021 and plunged 52.85% in 2025, its largest moves.
• Cue Biopharma's Assets Average stood at $81.1 million in 2021, then increased by 3.27% to $83.8 million in 2022, then dropped by 22.18% to $65.2 million in 2023, then plunged by 40.96% to $38.5 million in 2024, then dropped by 4.08% to $36.9 million in 2025.
• The last three Assets Average figures came in at $36.9 million (Q4 2025), $36.2 million (Q3 2025), and $31.5 million (Q2 2025), per Business Quant data.